{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:49:33Z","timestamp":1793209773793,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jhep.2017.11.039","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T22:31:05Z","timestamp":1516141865000},"page":"672-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":388,"title":["96\u202fweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"],"prefix":"10.1016","volume":"68","author":[{"given":"Kosh","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan\u2013Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin Q.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Kemal","family":"\u00c7elen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dr.","family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Tae","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Cathcart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeru","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithika","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mani Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry L.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.11.039_b0005","unstructured":"World Health Organization. Hepatitis B fact sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/."},{"key":"10.1016\/j.jhep.2017.11.039_b0010","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection\u2014natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.11.039_b0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mcna.2013.08.004","article-title":"Chronic hepatitis B virus infection","volume":"98","author":"McMahon","year":"2014","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jhep.2017.11.039_b0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.039_b0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2017.11.039_b0030","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.11.039_b0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.039_b0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.039_b0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.039_b0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/infdis\/jiu471","article-title":"Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: Can the fracture risk assessment tool identify those at greatest risk?","volume":"211","author":"Gill","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.11.039_b0055","doi-asserted-by":"crossref","first-page":"e2276","DOI":"10.1097\/MD.0000000000002276","article-title":"Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jhep.2017.11.039_b0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12882-015-0106-5","article-title":"13-year nationwide cohort study of chronic kidney disease risk among treatmen-na\u00efve patients with chronic hepatitis B in Taiwan","volume":"16","author":"Chen","year":"2015","journal-title":"BMC Nephrology"},{"key":"10.1016\/j.jhep.2017.11.039_b0065","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/jac\/dku502","article-title":"Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study","volume":"70","author":"Maggi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2017.11.039_b0070","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.11.039_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2017.11.039_b0080","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Delaney","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.11.039_b0085","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340","volume":"10","author":"Babusis","year":"2013","journal-title":"Mol Pharmaceutics"},{"key":"10.1016\/j.jhep.2017.11.039_b0090","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by TAF (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.11.039_b0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jhep.2017.11.039_b0100","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","volume":"35","author":"Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.11.039_b0105","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiv194","article-title":"Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate\/emtricitabine plus atazanavir\/ritonavir, darunavir\/ritonavir, or raltegravir","volume":"212","author":"Brown","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.11.039_b0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of TAF for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.039_b0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of TAF as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic"},{"key":"10.1016\/j.jhep.2017.11.039_b0120","first-page":"196","article-title":"TAF vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet","volume":"1","author":"Buti","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.039_b0125","first-page":"185","article-title":"TAF vs. tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet","volume":"1","author":"Chan","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.039_b0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos","year":"2015","journal-title":"Clin Infect Disease"},{"key":"10.1016\/j.jhep.2017.11.039_b0135","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","article-title":"A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2017.11.039_b0140","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/j.gastro.2013.12.028","article-title":"Randomized comparison of tenofovir disoproxil fumarate vs. emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B","volume":"146","author":"Fung","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.039_b0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jhep.2013.11.024","article-title":"Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients","volume":"60","author":"Berg","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.039_b0150","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00198-015-3037-x","article-title":"Erratum to: Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"26","author":"Cosman","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jhep.2017.11.039_b0155","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcv.2014.09.016","article-title":"Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal","volume":"61","author":"Vigan\u00f2","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2017.11.039_b0160","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3851\/IMP2649","article-title":"Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection","volume":"18","author":"Gracey","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.11.039_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2017.11.039_b0170","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0168-8278(17)30312-4","article-title":"Improved bone and renal safety of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): results from 2 Phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B","volume":"66","author":"Chan","year":"2017","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817324911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817324911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:08:01Z","timestamp":1660313281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817324911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0168827817324911"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"96\u202fweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}